Role of calcium, Vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 20-35

  Höbaus, Julia ^a   Thiem, Ursula ^a,b   Hummel, Doris M ^a   Kallay, Enikö ^a  

^a Department of Pathophysiology and Allergy Research ^*  (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

1 hydroxylase; 24 hydroxylase; 25 hydroxylase; Calcium; Calcium sensing receptor; Cancer; CaSR; Colorectal cancer; COX 2; CYP24A1; CYP27A1; CYP27B1; CYP2R1; Epigenetics; Methylation; Proliferation; Splice variants; Vitamin D; Wnt

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 25 HYDROXYLASE; 25 HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CHOLESTANETRIOL 26 MONOOXYGENASE; CYCLOOXYGENASE 2; MICRORNA; OXYGENASE; PROSTAGLANDIN E2; RETINOID X RECEPTOR; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

BREAST CANCER; CANCER RISK; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; COLON CANCER; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; RNA SPLICING; RNA STABILITY; UTERINE CERVIX CARCINOMA;

EID: 84878247928     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152013804487434     Document Type: Review

References (237)

1. Giovannucci, E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control, 2005, 16 (2), 83-95.
2. Cho, E.; Smith-Warner, S. A.; Spiegelman, D.; Beeson, W. L.; van den Brandt, P. A.; Colditz, G. A.; Folsom, A. R.; Fraser, G. E.; Freudenheim, J. L.; Giovannucci, E.; Goldbohm, R. A.; Graham, S.; Miller, A. B.; Pietinen, P.; Potter, J. D.; Rohan, T. E.; Terry, P.; Toniolo, P.; Virtanen, M. J.; Willett, W. C.; Wolk, A.; Wu, K.; Yaun, S. S.; Zeleniuch-Jacquotte, A.; Hunter, D. J. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J. Natl. Cancer Inst., 2004, 96 (13), 1015-1022.
3. Bouillon, R.; Van Cromphaut, S.; Carmeliet, G. Intestinal calcium absorption: Molecular vitamin D mediated mechanisms. J. Cell. Biochem., 2003, 88 (2), 332-339.
4. Fleet, J. C.; Schoch, R. D. Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit. Rev. Clin. Lab. Sci., 47 (4), 181-195.
5. Wasserman, R. H. Vitamin D and the dual processes of intestinal calcium absorption. J. Nutr., 2004, 134 (11), 3137-3139.
6. Kumar, R. Calcium transport in epithelial cells of the intestine and kidney. J. Cell. Biochem., 1995, 57 (3), 392-398.
7. Taketani, Y.; Segawa, H.; Chikamori, M.; Morita, K.; Tanaka, K.; Kido, S.; Yamamoto, H.; Iemori, Y.; Tatsumi, S.; Tsugawa, N.; Okano, T.; Kobayashi, T.; Miyamoto, K.; Takeda, E. Regulation of type II renal Na+-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D3. Identification of a vitamin Dresponsive element in the human NAPi-3 gene. J. Biol. Chem., 1998, 273 (23), 14575-14581.
8. Fleet, J. C. Molecular regulation of calcium and bone metabolism through the vitamin D receptor. J. Musculoskelet. Neuronal. Interact., 2006, 6 (4), 336-337.
9. Tfelt-Hansen, J.; Brown, E. M. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit. Rev. Clin. Lab. Sci., 2005, 42 (1), 35-70.
10. Capiod, T.; Shuba, Y.; Skryma, R.; Prevarskaya, N. Calcium signalling and cancer cell growth. Subcell. Biochem., 2007, 45, 405-427.
11. Peterlik, M.; Cross, H. S. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur. J. Clin. Invest., 2005, 35 (5), 290-304.
12. Peterlik, M.; Cross, H. S. Vitamin D and calcium insufficiencyrelated chronic diseases: molecular and cellular pathophysiology. Eur. J. Clin. Nutr., 2009, 63 (12), 1377-1386.
13. Peterlik, M.; Grant, W. B.; Cross, H. S. Calcium, vitamin D and cancer. Anticancer res., 2009, 29 (9), 3687-3698.
14. Garland, C.; Shekelle, R. B.; Barrett-Connor, E.; Criqui, M. H.; Rossof, A. H.; Paul, O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet, 1985, 1 (8424), 307-309.
15. Grau, M. V.; Baron, J. A.; Sandler, R. S.; Haile, R. W.; Beach, M. L.; Church, T. R.; Heber, D. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J. Natl. Cancer. Inst., 2003, 95 (23), 1765-1771.
16. Kallay, E.; Bises, G.; Bajna, E.; Bieglmayer, C.; Gerdenitsch, W.; Steffan, I.; Kato, S.; Armbrecht, H. J.; Cross, H. S. Colon-specific regulation of vitamin D hydroxylases--a possible approach for tumor prevention. Carcinogenesis, 2005, 26 (9), 1581-1589.
17. Holt, P. R.; Bresalier, R. S.; Ma, C. K.; Liu, K. F.; Lipkin, M.; Byrd, J. C.; Yang, K. Calcium plus vitamin D alters preneoplastic features of colorectal adenomas and rectal mucosa. Cancer, 2006, 106 (2), 287-296.
18. Cross, H. S.; Kallay, E. Nutritional regulation of extrarenal vitamin D hydroxylase expression-potential application in tumor prevention and therapy. Future Oncol., 2005, 1 (3), 415-424.
19. Lappe, J. M.; Travers-Gustafson, D.; Davies, K. M.; Recker, R. R.; Heaney, R. P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr., 2007, 85 (6), 1586-1591.
20. Masala, G.; Ambrogetti, D.; Assedi, M.; Giorgi, D.; Del Turco, M. R.; Palli, D. Dietary and lifestyle determinants of mammographic breast density. A longitudinal study in a Mediterranean population. Int. J. Cancer, 2006, 118 (7), 1782-1789.
21. Bolland, M. J.; Grey, A.; Gamble, G. D.; Reid, I. R. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am.J. clin. Nutr., 2011, 94 (4), 1144-1149.
22. Rodriguez, C.; McCullough, M. L.; Mondul, A. M.; Jacobs, E. J.; Fakhrabadi-Shokoohi, D.; Giovannucci, E. L.; Thun, M. J.; Calle, E. E. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003, 12 (7), 597-603.
23. Lou, Y. R.; Qiao, S.; Talonpoika, R.; Syvala, H.; Tuohimaa, P. The role of Vitamin D3 metabolism in prostate cancer. J. Steroid Biochem. Mol. Biol., 2004, 92 (4), 317-325.
24. Baron, J. A.; Beach, M.; Wallace, K.; Grau, M. V.; Sandler, R. S.; Mandel, J. S.; Heber, D.; Greenberg, E. R. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol. Biomarkers Prev., 2005, 14 (3), 586-589.
25. Huncharek, M.; Muscat, J.; Kupelnick, B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr. Cancer, 2008, 60 (4), 421-441.
26. Bonjour, J. P.; Chevalley, T.; Fardellone, P. Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. Br. J. Nutr., 2007, 97 (4), 611-616.
27. Bertone-Johnson, E. R.; McTiernan, A.; Thomson, C. A.; Wactawski-Wende, J.; Aragaki, A. K.; Rohan, T. E.; Vitolins, M. Z.; Tamimi, R. M.; Johnson, K. C.; Lane, D.; Rexrode, K. M.; Peck, J. D.; Chlebowski, R. T.; Sarto, G.; Manson, J. E. Vitamin D and Calcium Supplementation and One-Year Change in Mammographic Density in the Women's Health Initiative Calcium and Vitamin D Trial. Cancer Epidemiol. Biomarkers Prev., 2012, 21 (3), 462-473.
28. Avenell, A.; MacLennan, G. S.; Jenkinson, D. J.; McPherson, G. C.; McDonald, A. M.; Pant, P. R.; Grant, A. M.; Campbell, M. K.; Anderson, F. H.; Cooper, C.; Francis, R. M.; Gillespie, W. J.; Robinson, C. M.; Torgerson, D. J.; Wallace, W. A. Long-term follow-up for mortality and cancer in a randomized placebocontrolled trial of vitamin D(3) and/or calcium (RECORD trial). J. Clin. Endocrinol. Metab., 2012, 97 (2), 614-622.
29. Chung, M.; Lee, J.; Terasawa, T.; Lau, J.; Trikalinos, T. A. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2011, 155 (12), 827-838.
30. Ray, R.; Banks, M.; Abuzahra, H.; Eddy, V. J.; Persons, K. S.; Lucia, M. S.; Lambert, J. R.; Holick, M. F. Effect of Dietary Vitamin D and Calcium on the Growth of Androgen-insensitive Human Prostate Tumor in a Murine Model. Anticancer res., 2012, 32 (3), 727-731.
31. Newmark, H. L.; Yang, K.; Kurihara, N.; Fan, K.; Augenlicht, L. H.; Lipkin, M. Western-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer. Carcinogenesis, 2009, 30 (1), 88-92.
32. Yang, K.; Kurihara, N.; Fan, K.; Newmark, H.; Rigas, B.; Bancroft, L.; Corner, G.; Livote, E.; Lesser, M.; Edelmann, W.; Velcich, A.; Lipkin, M.; Augenlicht, L. Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Res., 2008, 68 (19), 7803-7810.
33. Kurihara, N.; Fan, K.; Thaler, H. T.; Yang, K.; Lipkin, M. Effect of a Western-style diet fortified with increased calcium and vitamin D on mammary gland of C57BL/6 mice. J. Med. Food., 2008, 11 (2), 201-206.
34. Xue, L.; Lipkin, M.; Newmark, H.; Wang, J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J. Natl. Cancer Inst., 1999, 91 (2), 176-181.
35. Hohman, E. E.; Martin, B. R.; Lachcik, P. J.; Gordon, D. T.; Fleet, J. C.; Weaver, C. M. Bioavailability and efficacy of vitamin D2 from UV-irradiated yeast in growing, vitamin D-deficient rats. J. Agric. Food Chem., 2011, 59 (6), 2341-2346.
36. Calvo, M. S.; Babu, U. S.; Garthoff, L. H.; Woods, T. O.; Dreher, M.; Hill, G.; Nagaraja, S. Vitamin D(2) from light-exposed edible mushrooms is safe, bioavailable and effectively supports bone growth in rats. Osteoporos. Int., 2012.
37. Jones, G.; Prosser, D. E. In: Vitamin D Feldman, D., Pike, W.J., Adams, J.S., Ed.; Elsevier, 2011; Vol. 1, pp. 23-42.
38. Nittke, T.; Kallay, E.; Manhardt, T.; Cross, H. S. Parallel elevation of colonic 1,25-dihydroxyvitamin D3 levels and apoptosis in female mice on a calcium-deficient diet. Anticancer Res., 2009, 29 (9), 3727-3732.
39. Wagner, D.; Dias, A. G.; Schnabl, K.; Van der Kwast, T.; Vieth, R. Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. Anticancer Res., 2012, 32 (1), 259-263.
40. Ponchon, G.; Kennan, A. L.; DeLuca, H.F. Activation of vitamin D by the liver. J. Clin. Invest., 1969, 48 (11), 2032-2037.
41. Ponchon, G.; DeLuca, H. F. The role of the liver in the metabolism of vitamin D. J. Clin. Invest., 1969, 48 (7), 1273-1279.
42. Yamasaki, T.; Izumi, S.; Ide, H.; Ohyama, Y. Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J. Biol. Chem., 2004, 279 (22), 22848-22856.
43. Hosseinpour, F.; Ibranovic, I.; Tang, W.; Wikvall, K. 25-Hydroxylation of vitamin D3 in primary cultures of pig hepatocytes: evidence for a role of both CYP2D25 and CYP27A1. Biochem. Biophys. Res. Commun., 2003, 303 (3), 877-883.
44. Cali, J. J.; Russell, D. W. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J. Biol. Chem., 1991, 266 (12), 7774-7778.
45. Guo, Y. D.; Strugnell, S.; Back, D. W.; Jones, G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc. Natl. Acad. Sci. U. S. A., 1993, 90 (18), 8668-8672.
46. Strugnell, S.; Byford, V.; Makin, H. L.; Moriarty, R. M.; Gilardi, R.; LeVan, L. W.; Knutson, J. C.; Bishop, C. W.; Jones, G. 1 alpha,24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B. Biochem. J., 1995, 310 (Pt 1), 233-241.
47. Shinkyo, R.; Sakaki, T.; Kamakura, M.; Ohta, M.; Inouye, K. Metabolism of vitamin D by human microsomal CYP2R1. Biochem. Biophys. Res. Commun., 2004, 324 (1), 451-457.
48. Jones, G.; Byford, V.; West, S.; Masuda, S.; Ibrahim, G.; Kaufmann, M.; Knutson, J. C.; Strugnell, S.; Mehta, R. Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res., 2006, 26 (4A), 2589-2595.
49. Andersson, S.; Davis, D. L.; Dahlback, H.; Jornvall, H.; Russell, D. W. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem., 1989, 264 (14), 8222-8229.
50. Ohyama, Y.; Masumoto, O.; Usui, E.; Okuda, K. Multi-functional property of rat liver mitochondrial cytochrome P-450. J. Biochem., 1991, 109 (3), 389-393.
51. Rosen, H.; Reshef, A.; Maeda, N.; Lippoldt, A.; Shpizen, S.; Triger, L.; Eggertsen, G.; Bjorkhem, I.; Leitersdorf, E. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J. Biol. Chem., 1998, 273 (24), 14805-14812.
52. Repa, J. J.; Lund, E. G.; Horton, J. D.; Leitersdorf, E.; Russell, D. W.; Dietschy, J. M.; Turley, S. D. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J. Biol. Chem., 2000, 275 (50), 39685-39692.
53. Cheng, J. B.; Motola, D. L.; Mangelsdorf, D. J.; Russell, D. W. Deorphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem, 2003, 278 (39), 38084-38093.
54. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta, 2011, 1814 (1), 186-199.
55. Wang, T. J.; Zhang, F.; Richards, J. B.; Kestenbaum, B.; van Meurs, J. B.; Berry, D.; Kiel, D. P.; Streeten, E. A.; Ohlsson, C.; Koller, D. L.; Peltonen, L.; Cooper, J. D.; O'Reilly, P. F.; Houston, D. K.; Glazer, N. L.; Vandenput, L.; Peacock, M.; Shi, J.; Rivadeneira, F.; McCarthy, M. I.; Anneli, P.; de Boer, I. H.; Mangino, M.; Kato, B.; Smyth, D. J.; Booth, S. L.; Jacques, P. F.; Burke, G. L.; Goodarzi, M.; Cheung, C. L.; Wolf, M.; Rice, K.; Goltzman, D.; Hidiroglou, N.; Ladouceur, M.; Wareham, N. J.; Hocking, L. J.; Hart, D.; Arden, N. K.; Cooper, C.; Malik, S.; Fraser, W. D.; Hartikainen, A. L.; Zhai, G.; Macdonald, H. M.; Forouhi, N. G.; Loos, R. J.; Reid, D. M.; Hakim, A.; Dennison, E.; Liu, Y.; Power, C.; Stevens, H. E.; Jaana, L.; Vasan, R. S.; Soranzo, N.; Bojunga, J.; Psaty, B. M.; Lorentzon, M.; Foroud, T.; Harris, T. B.; Hofman, A.; Jansson, J. O.; Cauley, J. A.; Uitterlinden, A. G.; Gibson, Q.; Jarvelin, M. R.; Karasik, D.; Siscovick, D. S.; Econs, M. J.; Kritchevsky, S. B.; Florez, J. C.; Todd, J. A.; Dupuis, J.; Hypponen, E.; Spector, T. D. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010, 376 (9736), 180-188.
56. Simon, K. C.; Munger, K. L.; Kraft, P.; Hunter, D. J.; De Jager, P. L.; Ascherio, A. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J. Neurol., 2011, 258 (9), 1676-1682.
57. Bu, F. X.; Armas, L.; Lappe, J.; Zhou, Y.; Gao, G.; Wang, H. W.; Recker, R.; Zhao, L. J. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum. Genet., 2010, 128 (5), 549-556.
58. Ahn, J.; Yu, K.; Stolzenberg-Solomon, R.; Simon, K. C.; McCullough, M. L.; Gallicchio, L.; Jacobs, E. J.; Ascherio, A.; Helzlsouer, K.; Jacobs, K. B.; Li, Q.; Weinstein, S. J.; Purdue, M.; Virtamo, J.; Horst, R.; Wheeler, W.; Chanock, S.; Hunter, D. J.; Hayes, R. B.; Kraft, P.; Albanes, D. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet., 2010, 19 (13), 2739-2745.
59. Ramos-Lopez, E.; Bruck, P.; Jansen, T.; Herwig, J.; Badenhoop, K. CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab. Res. Rev., 2007, 23 (8), 631-636.
60. Signorello, L. B.; Shi, J.; Cai, Q.; Zheng, W.; Williams, S. M.; Long, J.; Cohen, S. S.; Li, G.; Hollis, B. W.; Smith, J. R.; Blot, W. J. Common Variation in Vitamin D Pathway Genes Predicts Circulating 25-Hydroxyvitamin D Levels among African Americans. PLoS One, 2011, 6 (12), e28623.
61. Cheng, J. B.; Levine, M. A.; Bell, N. H.; Mangelsdorf, D. J.; Russell, D. W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U.S. A., 2004, 101 (20), 7711-7715.
62. Hashizume, T.; Imaoka, S.; Mise, M.; Terauchi, Y.; Fujii, T.; Miyazaki, H.; Kamataki, T.; Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther., 2002, 300 (1), 298-304.
63. Aiba, I.; Yamasaki, T.; Shinki, T.; Izumi, S.; Yamamoto, K.; Yamada, S.; Terato, H.; Ide, H.; Ohyama, Y. Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids, 2006, 71 (10), 849-856.
64. Rahmaniyan, M.; Patrick, K.; Bell, N. H. Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24- hydroxylase. Am. J. Physiol. Endocrinol. Metab., 2005, 288 (4), E753-760.
65. Masumoto, O.; Ohyama, Y.; Okuda, K. Purification and characterization of vitamin D 25-hydroxylase from rat liver mitochondria. J. Biol. Chem., 1988, 263 (28), 14256-14260.
66. Saarem, K.; Pedersen, J. I. Sex differences in the hydroxylation of cholecalciferol and of 5 beta-cholestane-3 alpha, 7 alpha, 12 alphatriol in rat liver. Biochem. J., 1987, 247 (1), 73-78.
67. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug. Metab., 2008, 9 (4), 310-322.
68. Gupta, R. P.; He, Y. A.; Patrick, K. S.; Halpert, J. R.; Bell, N. H. CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J. Clin. Endocrinol. Metab., 2005, 90 (2), 1210-1219.
69. Xu, Y.; Hashizume, T.; Shuhart, M. C.; Davis, C. L.; Nelson, W. L.; Sakaki, T.; Kalhorn, T. F.; Watkins, P. B.; Schuetz, E. G.; Thummel, K. E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol. Pharmacol., 2006, 69 (1), 56-65.
70. Townsend, K.; Evans, K. N.; Campbell, M. J.; Colston, K. W.; Adams, J. S.; Hewison, M. Biological actions of extra-renal 25- hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol., 2005, 97 (1-2), 103-109.
71. Dusso, A. S.; Brown, A. J.; Slatopolsky, E. Vitamin D. Am. J. Physiol. Renal Physiol., 2005, 289 (1), F8-28.
72. Henry, H. L. Regulation of vitamin D metabolism. Best Pract. Res. Clin. Endocrinol. Metab., 2011, 25 (4), 531-541.
73. Tang, E. K.; Voo, K. J.; Nguyen, M. N.; Tuckey, R. C. Metabolism of substrates incorporated into phospholipid vesicles by mouse 25- hydroxyvitamin D3 1alpha-hydroxylase (CYP27B1). J. Steroid Biochem. Mol. Biol., 2010, 119 (3-5), 171-179.
74. Malloy, P. J.; Feldman, D. Genetic disorders and defects in vitamin d action. Endocrinol. Metab. Clin. North. Am., 2010, 39 (2), 333-346, table of contents.
75. Kim, C. J.; Kaplan, L. E.; Perwad, F.; Huang, N.; Sharma, A.; Choi, Y.; Miller, W. L.; Portale, A. A. Vitamin D 1alphahydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 2007, 92 (8), 3177-3182.
76. Ramagopalan, S. V.; Dyment, D. A.; Cader, M. Z.; Morrison, K. M.; Disanto, G.; Morahan, J. M.; Berlanga-Taylor, A. J.; Handel, A.; De Luca, G. C.; Sadovnick, A. D.; Lepage, P.; Montpetit, A.; Ebers, G. C. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol., 2011, 70 (6), 881-886.
77. Sakaki, T.; Sawada, N.; Komai, K.; Shiozawa, S.; Yamada, S.; Yamamoto, K.; Ohyama, Y.; Inouye, K. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem., 2000, 267 (20), 6158-6165.
78. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta, 2011, 1814 (1), 186-199.
79. Prosser, D. E.; Jones, G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci., 2004, 29 (12), 664-673.
80. Sakaki, T.; Sawada, N.; Nonaka, Y.; Ohyama, Y.; Inouye, K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha,25- dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem., 1999, 262 (1), 43-48.
81. Kaufmann, M.; Prosser, D. E.; Jones, G. Bioengineering anabolic vitamin D-25-hydroxylase activity into the human vitamin D catabolic enzyme, cytochrome P450 CYP24A1, by a V391L mutation. J. Biol. Chem., 2011, 286 (33), 28729-28737.
82. Roy, S.; Martel, J.; Ma, S.; Tenenhouse, H. S. Increased renal 25- hydroxyvitamin D3-24-hydroxylase messenger ribonucleic acid and immunoreactive protein in phosphate-deprived Hyp mice: a mechanism for accelerated 1,25-dihydroxyvitamin D3 catabolism in X-linked hypophosphatemic rickets. Endocrinology, 1994, 134 (4), 1761-1767.
83. Helvig, C. F.; Cuerrier, D.; Hosfield, C. M.; Ireland, B.; Kharebov, A. Z.; Kim, J. W.; Ramjit, N. J.; Ryder, K.; Tabash, S. P.; Herzenberg, A. M.; Epps, T. M.; Petkovich, M. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int., 2010, 78 (5), 463-472.
84. Schlingmann, K. P.; Kaufmann, M.; Weber, S.; Irwin, A.; Goos, C.; John, U.; Misselwitz, J.; Klaus, G.; Kuwertz-Bröking, E.; Fehrenbach, H.; Wingen, A. M.; Güran, T.; Hoenderop, J. G.; Bindels, R. J.; Prosser, D. E.; Jones, G.; Konrad, M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med., 2011, 365 (5), 410-421.
85. Dauber, A.; Nguyen, T. T.; Sochett, E.; Cole, D. E.; Horst, R.; Abrams, S. A.; Carpenter, T. O.; Hirschhorn, J. N. Genetic Defect in CYP24A1, the Vitamin D 24-Hydroxylase Gene, in a Patient with Severe Infantile Hypercalcemia. J. Clin. Endocrinol. Metab., 2011.
86. Tebben, P. J.; Milliner, D. S.; Horst, R. L.; Harris, P. C.; Singh, R. J.; Wu, Y.; Foreman, J. W.; Chelminski, P. R.; Kumar, R. Hypercalcemia, Hypercalciuria, and Elevated Calcitriol Concentrations with Autosomal Dominant Transmission Due to CYP24A1 Mutations: Effects of Ketoconazole Therapy. J. Clin. Endocrinol. Metab., 2012, 97 (3), E423-427.
87. Grant, W. B.; Cross, H. S.; Garland, C. F.; Gorham, E. D.; Moan, J.; Peterlik, M.; Porojnicu, A. C.; Reichrath, J.; Zittermann, A. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog. Biophys. Mol. Biol., 2009, 99 (2-3), 104-113.
88. Garland, C. F.; Gorham, E. D.; Mohr, S. B.; Garland, F. C. Vitamin D for cancer prevention: global perspective. Ann. Epidemiol., 2009, 19 (7), 468-483.
89. Putz-Bankuti, C.; Pilz, S.; Stojakovic, T.; Scharnagl, H.; Pieber, T. R.; Trauner, M.; Obermayer-Pietsch, B.; Stauber, R. E. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int., 2012.
90. Gascon-Barre, M.; Demers, C.; Ghrab, O.; Theodoropoulos, C.; Lapointe, R.; Jones, G.; Valiquette, L.; Menard, D. Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney. Clin. Endocrinol. (Oxf), 2001, 54 (1), 107-115.
91. Blomberg Jensen, M.; Andersen, C. B.; Nielsen, J. E.; Bagi, P.; Jorgensen, A.; Juul, A.; Leffers, H. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J. Steroid Biochem. Mol. Biol., 2010, 121 (1-2), 376-382.
92. Correa, P.; Segersten, U.; Hellman, P.; Akerstrom, G.; Westin, G. Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d. J. Clin. Endocrinol. Metab., 2002, 87 (12), 5826-5829.
93. Blomberg Jensen, M.; Nielsen, J. E.; Jorgensen, A.; Rajpert-De Meyts, E.; Kristensen, D. M.; Jorgensen, N.; Skakkebaek, N. E.; Juul, A.; Leffers, H. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum. Reprod., 2010, 25 (5), 1303-1311.
94. Ellfolk, M.; Norlin, M.; Gyllensten, K.; Wikvall, K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol. Pharmacol., 2009, 75 (6), 1392-1399.
95. Flanagan, J. N.; Young, M. V.; Persons, K. S.; Wang, L.; Mathieu, J. S.; Whitlatch, L. W.; Holick, M. F.; Chen, T. C. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res., 2006, 26 (4A), 2567-2572.
96. Tokar, E. J.; Webber, M. M. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin. Exp. Metastasis, 2005, 22 (3), 275-284.
97. Zhu, J.; Deluca, H. F. Vitamin D 25-hydroxylase-Four decades of searching, are we there yet? Arch. Biochem. Biophys., 2012.
98. Zehnder, D.; Bland, R.; Williams, M. C.; McNinch, R. W.; Howie, A. J.; Stewart, P. M.; Hewison, M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab., 2001, 86 (2), 888-894.
99. Zehnder, D.; Bland, R.; Chana, R. S.; Wheeler, D. C.; Howie, A. J.; Williams, M. C.; Stewart, P. M.; Hewison, M. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol., 2002, 13 (3), 621-629.
100. Bareis, P.; Kállay, E.; Bischof, M. G.; Bises, G.; Hofer, H.; Pötzi, C.; Manhardt, T.; Bland, R.; Cross, H. S. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Exp. Cell Res., 2002, 276 (2), 320-327.
101. Avila, E.; Díaz, L.; Barrera, D.; Arranz, C.; Halhali, A.; Larrea, F. Metabolism of vitamin D in the human choriocarcinoma cell line JEG-3. J. Steroid Biochem. Mol. Biol., 2007, 103 (3-5), 781-785.
102. Kloss, M.; Fischer, D.; Thill, M.; Friedrich, M.; Cordes, T.; Salehin, D.; Diedrich, K.; Köster, F. Vitamin D, calcidiol and calcitriol regulate vitamin D metabolizing enzymes in cervical and ovarian cancer cells. Anticancer Res., 2010, 30 (11), 4429-4434.
103. Diesel, B.; Radermacher, J.; Bureik, M.; Bernhardt, R.; Seifert, M.; Reichrath, J.; Fischer, U.; Meese, E. Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin. Cancer. Res., 2005, 11 (15), 5370-5380.
104. Cross, H. S.; Bareis, P.; Hofer, H.; Bischof, M. G.; Bajna, E.; Kriwanek, S.; Bonner, E.; Peterlik, M. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids, 2001, 66 (3-5), 287-292.
105. Bareis, P.; Bises, G.; Bischof, M. G.; Cross, H. S.; Peterlik, M. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun., 2001, 285 (4), 1012-1017.
106. Bises, G.; Kallay, E.; Weiland, T.; Wrba, F.; Wenzl, E.; Bonner, E.; Kriwanek, S.; Obrist, P.; Cross, H. S. 25-hydroxyvitamin D3-1alpha-hydroxylase expression in normal and malignant human colon. J. Histochem. Cytochem., 2004, 52 (7), 985-989.
107. Segersten, U.; Correa, P.; Hewison, M.; Hellman, P.; Dralle, H.; Carling, T.; Akerström, G.; Westin, G. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab., 2002, 87 (6), 2967-2972.
108. Schröder, O.; Turak, S.; Daniel, C.; Gaschott, T.; Stein, J. Upregulation of 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase by butyrate in Caco-2 cells. World J. Gastroenterol., 2005, 11 (45), 7136-7141.
109. Chen, T. C. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anticancer Res., 2008, 28 (4A), 2015-2017.
110. Cross, H. S.; Kállay, E.; Lechner, D.; Gerdenitsch, W.; Adlercreutz, H.; Armbrecht, H. J. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J. Nutr., 2004, 134 (5), 1207S-1212S.
111. Lechner, D.; Bajna, E.; Adlercreutz, H.; Cross, H. S. Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. Anticancer Res., 2006, 26 (4A), 2597-2603.
112. Sakamoto, K.; Maeda, S.; Hikiba, Y.; Nakagawa, H.; Hayakawa, Y.; Shibata, W.; Yanai, A.; Ogura, K.; Omata, M. Constitutive NFkappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res., 2009, 15 (7), 2248-2258.
113. Weichert, W.; Boehm, M.; Gekeler, V.; Bahra, M.; Langrehr, J.; Neuhaus, P.; Denkert, C.; Imre, G.; Weller, C.; Hofmann, H. P.; Niesporek, S.; Jacob, J.; Dietel, M.; Scheidereit, C.; Kristiansen, G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br. J. Cancer, 2007, 97 (4), 523-530.
114. Ebert, R.; Jovanovic, M.; Ulmer, M.; Schneider, D.; Meissner-Weigl, J.; Adamski, J.; Jakob, F. Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol. Endocrinol., 2004, 18 (10), 2440-2450.
115. Akeno, N.; Saikatsu, S.; Kawane, T.; Horiuchi, N. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology, 1997, 138 (6), 2233-2240.
116. Chen, S.; Glenn, D. J.; Ni, W.; Grigsby, C. L.; Olsen, K.; Nishimoto, M.; Law, C. S.; Gardner, D. G. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension, 2008, 52 (6), 1106-1112.
117. Meyer, M. B.; Zella, L. A.; Nerenz, R. D.; Pike, J. W. Characterizing early events associated with the activation of target genes by 1,25-dihydroxyvitamin D3 in mouse kidney and intestine in vivo. J. Biol. Chem., 2007, 282 (31), 22344-22352.
118. Friedrich, M.; Rafi, L.; Mitschele, T.; Tilgen, W.; Schmidt, W.; Reichrath, J. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res., 2003, 164, 239-246.
119. Anderson, M. G.; Nakane, M.; Ruan, X.; Kroeger, P. E.; Wu-Wong, J. R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol., 2006, 57 (2), 234-240.
120. Horváth, H. C.; Lakatos, P.; Kósa, J. P.; Bácsi, K.; Borka, K.; Bises, G.; Nittke, T.; Hershberger, P. A.; Speer, G.; Kállay, E. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J. Histochem. Cytochem., 2010, 58 (3), 277-285.
121. Parise, R. A.; Egorin, M. J.; Kanterewicz, B.; Taimi, M.; Petkovich, M.; Lew, A. M.; Chuang, S. S.; Nichols, M.; El-Hefnawy, T.; Hershberger, P. A. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer, 2006, 119 (8), 1819-1828.
122. Mimori, K.; Tanaka, Y.; Yoshinaga, K.; Masuda, T.; Yamashita, K.; Okamoto, M.; Inoue, H.; Mori, M. Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann. Oncol., 2004, 15 (2), 236-241.
123. Reichrath, J.; Rafi, L.; Rech, M.; Mitschele, T.; Meineke, V.; Gärtner, B. C.; Tilgen, W.; Holick, M. F. Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J. Cutan. Pathol., 2004, 31 (3), 224-231.
124. Brozyna, A. A.; Jozwicki, W.; Janjetovic, Z.; Slominski, A. T. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum. Pathol., 2011, 42 (5), 618-631.
125. Lopes, N.; Sousa, B.; Martins, D.; Gomes, M.; Vieira, D.; Veronese, L. A.; Milanezi, F.; Paredes, J.; Costa, J. L.; Schmitt, F. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer, 2010, 10, 483.
126. Thill, M.; Fischer, D.; Kelling, K.; Hoellen, F.; Dittmer, C.; Hornemann, A.; Salehin, D.; Diedrich, K.; Friedrich, M.; Becker, S. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J. Steroid. Biochem. Mol. Biol., 2010, 121 (1-2), 387-390.
127. Cross, H. S.; Bajna, E.; Bises, G.; Genser, D.; Kállay, E.; Pötzi, R.; Wenzl, E.; Wrba, F.; Roka, R.; Peterlik, M. Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer. Anticancer Res., 1996, 16 (4B), 2333-2337.
128. Miller, G. J.; Stapleton, G. E.; Hedlund, T. E.; Moffat, K. A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1995, 1 (9), 997-1003.
129. Albertson, D. G.; Ylstra, B.; Segraves, R.; Collins, C.; Dairkee, S. H.; Kowbel, D.; Kuo, W. L.; Gray, J. W.; Pinkel, D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet., 2000, 25 (2), 144-146.
130. Jubb, A. M.; Bell, S. M.; Quirke, P. Methylation and colorectal cancer. J. Pathol., 2001, 195 (1), 111-134.
131. Feinberg, A. P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983, 301 (5895), 89-92.
132. Goelz, S. E.; Vogelstein, B.; Hamilton, S. R.; Feinberg, A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science, 1985, 228 (4696), 187-190.
133. Herman, J. G.; Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 2003, 349 (21), 2042-2054.
134. Shi, H.; Yan, P. S.; Chen, C. M.; Rahmatpanah, F.; Lofton-Day, C.; Caldwell, C. W.; Huang, T. H. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer. Res., 2002, 62 (11), 3214-3220.
135. Novakovic, B.; Sibson, M.; Ng, H. K.; Manuelpillai, U.; Rakyan, V.; Down, T.; Beck, S.; Fournier, T.; Evain-Brion, D.; Dimitriadis, E.; Craig, J. M.; Morley, R.; Saffery, R. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J. Biol. Chem., 2009, 284 (22), 14838-14848.
136. Khorchide, M.; Lechner, D.; Cross, H. S. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J. Steroid Biochem. Mol. Biol., 2005, 93 (2-5), 167-172.
137. Ohyama, Y.; Kusada, T.; Yamasaki, T.; Ide, H. Extensive methylation of CpG island of CYP24 gene in osteoblastic ROS17/2.8 cells. Nucleic Acids Res. Suppl., 2002, (2), 249-250.
138. Chung, I.; Karpf, A. R.; Muindi, J. R.; Conroy, J. M.; Nowak, N. J.; Johnson, C. S.; Trump, D. L. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. J. Biol. Chem., 2007, 282 (12), 8704-8714.
139. Luo, W.; Karpf, A. R.; Deeb, K. K.; Muindi, J. R.; Morrison, C. D.; Johnson, C. S.; Trump, D. L. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res., 2010, 70 (14), 5953-5962.
140. Deeb, K. K.; Luo, W.; Karpf, A. R.; Omilian, A. R.; Bshara, W.; Tian, L.; Tangrea, M. A.; Morrison, C. D.; Johnson, C. S.; Trump, D. L. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics, 2011, 6 (8), 994-1000.
141. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144 (5), 646-674.
142. Reifenberger, G.; Reifenberger, J.; Ichimura, K.; Meltzer, P. S.; Collins, V. P. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res., 1994, 54 (16), 4299-4303.
143. Maas, R. M.; Reus, K.; Diesel, B.; Steudel, W. I.; Feiden, W.; Fischer, U.; Meese, E. Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,alpha-hydroxylase (CYP 27B1) in human malignant glioma. Clin. Cancer Res., 2001, 7 (4), 868-875.
144. Fischer, U.; Leidinger, P.; Keller, A.; Folarin, A.; Ketter, R.; Graf, N.; Lenhof, H. P.; Meese, E. Amplicons on chromosome 12q13-21 in glioblastoma recurrences. Int. J. Cancer, 2010, 126 (11), 2594-2602.
145. Squire, J. A.; Pei, J.; Marrano, P.; Beheshti, B.; Bayani, J.; Lim, G.; Moldovan, L.; Zielenska, M. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer, 2003, 38 (3), 215-225.
146. Atiye, J.; Wolf, M.; Kaur, S.; Monni, O.; Böhling, T.; Kivioja, A.; Tas, E.; Serra, M.; Tarkkanen, M.; Knuutila, S. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer, 2005, 42 (2), 158-163.
147. Hawkins, G. A.; Cramer, S. D.; Zheng, S. L.; Isaacs, S. D.; Wiley, K. E.; Chang, B. L.; Bleecker, E. R.; Walsh, P. C.; Meyers, D. A.; Isaacs, W. B.; Xu, J. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate, 2002, 53 (3), 175-178.
148. Bonilla, C.; Hooker, S.; Mason, T.; Bock, C. H.; Kittles, R. A. Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans. PLoS One, 2011, 6 (2), e16044.
149. Holick, C. N.; Stanford, J. L.; Kwon, E. M.; Ostrander, E. A.; Nejentsev, S.; Peters, U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2007, 16 (10), 1990-1999.
150. Beuten, J.; Gelfond, J. A.; Franke, J. L.; Weldon, K. S.; Crandall, A. C.; Johnson-Pais, T. L.; Thompson, I. M.; Leach, R. J. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2009, 18 (6), 1869-1880.
151. Holt, S. K.; Kwon, E. M.; Koopmeiners, J. S.; Lin, D. W.; Feng, Z.; Ostrander, E. A.; Peters, U.; Stanford, J. L. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate, 2010, 70 (13), 1448-1460.
152. Dong, L. M.; Ulrich, C. M.; Hsu, L.; Duggan, D. J.; Benitez, D. S.; White, E.; Slattery, M. L.; Farin, F. M.; Makar, K. W.; Carlson, C. S.; Caan, B. J.; Potter, J. D.; Peters, U. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev., 2009, 18 (9), 2540-2548.
153. Lauter, K.; Arnold, A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J. Bone Miner. Res., 2009, 24 (1), 102-104.
154. Wong, M. P.; Fung, L. F.; Wang, E.; Chow, W. S.; Chiu, S. W.; Lam, W. K.; Ho, K. K.; Ma, E. S.; Wan, T. S.; Chung, L. P. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer, 2003, 97 (5), 1263-1270.
155. Hidaka, S.; Yasutake, T.; Takeshita, H.; Kondo, M.; Tsuji, T.; Nanashima, A.; Sawai, T.; Yamaguchi, H.; Nakagoe, T.; Ayabe, H.; Tagawa, Y. Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin. Cancer Res., 2000, 6 (7), 2712-2717.
156. Rygiel, A. M.; Milano, F.; Ten Kate, F. J.; Schaap, A.; Wang, K. K.; Peppelenbosch, M. P.; Bergman, J. J.; Krishnadath, K. K. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev., 2008, 17 (6), 1380-1385.
157. Meijer, G. A.; Hermsen, M. A.; Baak, J. P.; van Diest, P. J.; Meuwissen, S. G.; Beliën, J. A.; Hoovers, J. M.; Joenje, H.; Snijders, P. J.; Walboomers, J. M. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J. Clin. Pathol., 1998, 51 (12), 901-909.
158. Sillars-Hardebol, A. H.; Carvalho, B.; Tijssen, M.; Beliën, J. A.; de Wit, M.; Delis-van Diemen, P. M.; Pontén, F.; van de Wiel, M. A.; Fijneman, R. J.; Meijer, G. A. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut, 2011.
159. Jones, G.; Prosser, D. E.; Kaufmann, M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch. Biochem. Biophys., 2011.
160. Roff, A.; Wilson, R. T. A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J. Steroid Biochem. Mol. Biol., 2008, 112 (1-3), 47-54.
161. Kostner, K.; Denzer, N.; Muller, C. S.; Klein, R.; Tilgen, W.; Reichrath, J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer research, 2009, 29 (9), 3511-3536.
162. Denzer, N.; Vogt, T.; Reichrath, J. Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol., 2011, 3 (3), 205-210.
163. Lu, J.; Getz, G.; Miska, E. A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B. L.; Mak, R. H.; Ferrando, A. A.; Downing, J. R.; Jacks, T.; Horvitz, H. R.; Golub, T. R. MicroRNA expression profiles classify human cancers. Nature, 2005, 435 (7043), 834-838.
164. Lovat, F.; Valeri, N.; Croce, C. M. MicroRNAs in the pathogenesis of cancer. Semin. Oncol., 2011, 38 (6), 724-733.
165. Meola, N.; Gennarino, V. A.; Banfi, S. microRNAs and genetic diseases. Pathogenetics, 2009, 2 (1), 7.
166. Diesel, B.; Seifert, M.; Radermacher, J.; Fischer, U.; Tilgen, W.; Reichrath, J.; Meese, E. Towards a complete picture of splice variants of the gene for 25-hydroxyvitamin D31alpha-hydroxylase in brain and skin cancer. J. Steroid Biochem. Mol. Biol., 2004, 89-90 (1-5), 527-532.
167. Wu, S.; Ren, S.; Nguyen, L.; Adams, J. S.; Hewison, M. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology, 2007, 148 (7), 3410-3418.
168. Cordes, T.; Diesing, D.; Becker, S.; Fischer, D.; Diedrich, K.; Friedrich, M. Expression of splice variants of 1alpha-hydroxylase in mcf-7 breast cancer cells. J. Steroid Biochem. Mol. Biol., 2007, 103 (3-5), 326-329.
169. Becker, S.; Cordes, T.; Diesing, D.; Diedrich, K.; Friedrich, M. Expression of 25 hydroxyvitamin D3-1alpha-hydroxylase in human endometrial tissue. J. Steroid Biochem. Mol. Biol., 2007, 103 (3-5), 771-775.
170. Fischer, D.; Thomé, M.; Becker, S.; Cordes, T.; Diedrich, K.; Friedrich, M.; Thill, M. 25-Hydroxyvitamin D3 1alphahydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res., 2009, 29 (9), 3627-3633.
171. Komagata, S.; Nakajima, M.; Takagi, S.; Mohri, T.; Taniya, T.; Yokoi, T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol., 2009, 76 (4), 702-709.
172. Mohri, T.; Nakajima, M.; Takagi, S.; Komagata, S.; Yokoi, T. MicroRNA regulates human vitamin D receptor. Int. J. Cancer, 2009, 125 (6), 1328-1333.
173. Matilainen, J. M.; Malinen, M.; Turunen, M. M.; Carlberg, C.; Väisänen, S. The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells. J. Biol. Chem., 2010, 285 (31), 24174-24183.
174. Ren, S.; Nguyen, L.; Wu, S.; Encinas, C.; Adams, J. S.; Hewison, M. Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem., 2005, 280 (21), 20604-20611.
175. Horváth, H. C.; Khabir, Z.; Nittke, T.; Gruber, S.; Speer, G.; Manhardt, T.; Bonner, E.; Kallay, E. CYP24A1 splice variants--implications for the antitumorigenic actions of 1,25-(OH)2D3 in colorectal cancer. J. Steroid Biochem. Mol. Biol., 2010, 121 (1-2), 76-79.
176. Muindi, J. R.; Nganga, A.; Engler, K. L.; Coignet, L. J.; Johnson, C. S.; Trump, D. L. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. J. Steroid Biochem. Mol. Biol., 2007, 103 (3-5), 334-337.
177. Blomberg Jensen, M.; Nielsen, J. E.; Jørgensen, A.; Rajpert-De Meyts, E.; Kristensen, D. M.; Jørgensen, N.; Skakkebaek, N. E.; Juul, A.; Leffers, H. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum. Reprod., 2010, 25 (5), 1303-1311.
178. Sun, Z.; Wang, P. P.; Roebothan, B.; Cotterchio, M.; Green, R.; Buehler, S.; Zhao, J.; Squires, J.; Zhu, Y.; Dicks, E.; Campbell, P. T.; McLaughlin, J. R.; Parfrey, P. S. Calcium and vitamin D and risk of colorectal cancer: results from a large population-based case-control study in Newfoundland and Labrador and Ontario. Can. J. Public Health, 2011, 102 (5), 382-389.
179. Gorham, E. D.; Garland, C. F.; Garland, F. C.; Grant, W. B.; Mohr, S. B.; Lipkin, M.; Newmark, H. L.; Giovannucci, E.; Wei, M.; Holick, M. F. Vitamin D and prevention of colorectal cancer. J. Steroid Biochem. Mol. Biol., 2005, 97 (1-2), 179-194.
180. Peterlik, M. Role of bile acid secretion in human colorectal cancer. Wien. Med. Wochenschr., 2008, 158 (19-20), 539-541.
181. Nehring, J. A.; Zierold, C.; DeLuca, H. F. Lithocholic acid can carry out in vivo functions of vitamin D. Proc. Natl. Acad. Sci. U S A, 2007, 104 (24), 10006-10009.
182. Chakrabarty, S.; Wang, H.; Canaff, L.; Hendy, G. N.; Appelman, H.; Varani, J. Calcium sensing receptor in human colon carcinoma: interaction with Ca(2+) and 1,25-dihydroxyvitamin D(3). Cancer Res., 2005, 65 (2), 493-498.
183. Canaff, L.; Hendy, G. N. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J. Biol. Chem., 2002, 277 (33), 30337-30350.
184. Rey, O.; Chang, W.; Bikle, D.; Rozengurt, N.; Young, S. H.; Rozengurt, E. Negative cross-talk between calcium-sensing receptor and beta-catenin signaling systems in colonic epithelium. J. Biol. Chem., 2012, 287 (2), 1158-1167.
185. Saidak, Z.; Mentaverri, R.; Brown, E. M. The role of the calciumsensing receptor in the development and progression of cancer. Endocr. Rev., 2009, 30 (2), 178-195.
186. Kallay, E.; Bonner, E.; Wrba, F.; Thakker, R. V.; Peterlik, M.; Cross, H. S. Molecular and functional characterization of the extracellular calcium-sensing receptor in human colon cancer cells. Oncol. Res., 2003, 13 (12), 551-559.
187. Chakrabarty, S.; Radjendirane, V.; Appelman, H.; Varani, J. Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res., 2003, 63 (1), 67-71.
188. Whitfield, J. F. The calcium-sensing receptor--a driver of colon cell differentiation. Curr. Pharm. Biotechnol., 2009, 10 (3), 311-316.
189. Sheinin, Y.; Kallay, E.; Wrba, F.; Kriwanek, S.; Peterlik, M.; Cross, H. S. Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa. J. Histochem. Cytochem., 2000, 48 (5), 595-602.
190. Kallay, E.; Bajna, E.; Wrba, F.; Kriwanek, S.; Peterlik, M.; Cross, H. S. Dietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor. Cancer Detect. Prev., 2000, 24 (2), 127-136.
191. Koh, J.; Dar, M.; Untch, B. R.; Dixit, D.; Shi, Y.; Yang, Z.; Adam, M. A.; Dressman, H.; Wang, X.; Gesty-Palmer, D.; Marks, J. R.; Spurney, R.; Druey, K. M.; Olson, J.A., Jr. Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor. Mol. Endocrinol., 2011, 25 (5), 867-876.
192. Chakravarti, B.; Dwivedi, S. K.; Mithal, A.; Chattopadhyay, N. Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine, 2009, 35 (3), 271-284.
193. Mamillapalli, R.; VanHouten, J.; Zawalich, W.; Wysolmerski, J. Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J. Biol. Chem., 2008, 283 (36), 24435-24447.
194. Tharmalingam, S.; Daulat, A. M.; Antflick, J. E.; Ahmed, S. M.; Nemeth, E. F.; Angers, S.; Conigrave, A. D.; Hampson, D. R. Calcium-sensing receptor modulates cell adhesion and migration via integrins. J. Biol. Chem., 2011, 286 (47), 40922-40933.
195. MacLeod, R. J.; Hayes, M.; Pacheco, I. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293 (1), G403-411.
196. Goss, K. H.; Groden, J. Biology of the adenomatous polyposis coli tumor suppressor. J. Clin. Oncol., 2000, 18 (9), 1967-1979.
197. Byers, S. W.; Rowlands, T.; Beildeck, M.; Bong, Y. S. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev. Endocr. Metab. Disord., 2012, 13 (1), 31-38.
198. Pendas-Franco, N.; Aguilera, O.; Pereira, F.; Gonzalez-Sancho, J. M.; Munoz, A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res., 2008, 28 (5A), 2613-2623.
199. Shah, S.; Islam, M. N.; Dakshanamurthy, S.; Rizvi, I.; Rao, M.; Herrell, R.; Zinser, G.; Valrance, M.; Aranda, A.; Moras, D.; Norman, A.; Welsh, J.; Byers, S. W. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell, 2006, 21 (6), 799-809.
200. Greenhough, A.; Smartt, H. J.; Moore, A. E.; Roberts, H. R.; Williams, A. C.; Paraskeva, C.; Kaidi, A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30 (3), 377-386.
201. Wang, D.; Dubois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer, 10 (3), 181-193.
202. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56 (3), 387-437.
203. Bises, G.; Bajna, E.; Manhardt, T.; Gerdenitsch, W.; Kallay, E.; Cross, H. S. Gender-specific modulation of markers for premalignancy by nutritional soy and calcium in the mouse colon. J. Nutr., 2007, 137 (1 Suppl), 211S-215S.
204. Kallay, E.; Kifor, O.; Chattopadhyay, N.; Brown, E. M.; Bischof, M. G.; Peterlik, M.; Cross, H. S. Calcium-dependent c-myc protooncogene expression and proliferation of Caco-2 cells: a role for a luminal extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun., 1997, 232 (1), 80-83.
205. Nittke, T.; Selig, S.; Kallay, E.; Cross, H. S. Nutritional calcium modulates colonic expression of vitamin D receptor and pregnane X receptor target genes. Mol. Nutr. Food. Res., 2008, 52 Suppl 1, S45-51.
206. Moreno, J.; Krishnan, A. V.; Swami, S.; Nonn, L.; Peehl, D. M.; Feldman, D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res., 2005, 65 (17), 7917-7925.
207. Krishnan, A. V.; Moreno, J.; Nonn, L.; Malloy, P.; Swami, S.; Peng, L.; Peehl, D. M.; Feldman, D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol., 2007, 103 (3-5), 694-702.
208. Adorini, L.; Penna, G.; Giarratana, N.; Roncari, A.; Amuchastegui, S.; Daniel, K. C.; Uskokovic, M. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol., 2004, 89-90 (1-5), 437-441.
209. Penna, G.; Adorini, L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol., 2000, 164 (5), 2405-2411.
210. Prietl, B.; Pilz, S.; Wolf, M.; Tomaschitz, A.; Obermayer-Pietsch, B.; Graninger, W.; Pieber, T. R. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr. Med. Assoc. J., 2010, 12 (3), 136-139.
211. Zamarron, B. F.; Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci., 2011, 7 (5), 651-658.
212. Dahlback, H.; Wikvall, K. 25-Hydroxylation of vitamin D3 by a cytochrome P-450 from rabbit liver mitochondria. Biochem. J., 1988, 252 (1), 207-213.
213. Sawada, N.; Sakaki, T.; Ohta, M.; Inouye, K. Metabolism of vitamin D(3) by human CYP27A1. Biochem. Biophys. Res. Commun., 2000, 273 (3), 977-984.
214. Zhang, Q. Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L. S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 1999, 27 (7), 804-809.
215. Gupta, R. P.; Hollis, B. W.; Patel, S. B.; Patrick, K. S.; Bell, N. H. CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J. Bone. Miner. Res., 2004, 19 (4), 680-688.
216. Aleksa, K.; Matsell, D.; Krausz, K.; Gelboin, H.; Ito, S.; Koren, G. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr. Nephrol., 2005, 20 (7), 872-885.
217. Bergheim, I.; Bode, C.; Parlesak, A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin. Pharmacol., 2005, 5, 4.
218. Ghosh, C.; Marchi, N.; Desai, N. K.; Puvenna, V.; Hossain, M.; Gonzalez-Martinez, J.; Alexopoulos, A. V.; Janigro, D. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia, 2011, 52 (3), 562-571.
219. Enayetallah, A. E.; French, R. A.; Thibodeau, M. S.; Grant, D. F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem., 2004, 52 (4), 447-454.
220. Wu, S.; Chen, W.; Murphy, E.; Gabel, S.; Tomer, K. B.; Foley, J.; Steenbergen, C.; Falck, J. R.; Moomaw, C. R.; Zeldin, D. C. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem., 1997, 272 (19), 12551-12559.
221. Imaoka, S.; Hashizume, T.; Funae, Y. Localization of rat cytochrome P450 in various tissues and comparison of arachidonic acid metabolism by rat P450 with that by human P450 orthologs. Drug. Metab. Pharmacokinet., 2005, 20 (6), 478-484.
222. Axen, E. Purification from pig kidney of a microsomal cytochrome P450 catalyzing 1 alpha-hydroxylation of 25-hydroxyvitamin D3. FEBS Lett., 1995, 375 (3), 277-279.
223. Ogunkolade, B. W.; Boucher, B. J.; Fairclough, P. D.; Hitman, G. A.; Dorudi, S.; Jenkins, P. J.; Bustin, S. A. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer. Lancet, 2002, 359 (9320), 1831-1832.
224. McCarthy, K.; Laban, C.; Bustin, S. A.; Ogunkolade, W.; Khalaf, S.; Carpenter, R.; Jenkins, P. J. Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res., 2009, 29 (1), 155-157.
225. Townsend, K.; Banwell, C. M.; Guy, M.; Colston, K. W.; Mansi, J. L.; Stewart, P. M.; Campbell, M. J.; Hewison, M. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer. Res., 2005, 11 (9), 3579-3586.
226. de Lyra, E. C.; da Silva, I. A.; Katayama, M. L.; Brentani, M. M.; Nonogaki, S.; Góes, J. C.; Folgueira, M. A. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J. Steroid Biochem. Mol. Biol., 2006, 100 (4-5), 184-192.
227. Ma, J. F.; Nonn, L.; Campbell, M. J.; Hewison, M.; Feldman, D.; Peehl, D. M. Mechanisms of decreased Vitamin D 1alphahydroxylase activity in prostate cancer cells. Mol. Cell. Endocrinol., 2004, 221 (1-2), 67-74.
228. Chen, T. C.; Wang, L.; Whitlatch, L. W.; Flanagan, J. N.; Holick, M. F. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell. Biochem., 2003, 88 (2), 315-322.
229. Hsu, J. Y.; Feldman, D.; McNeal, J. E.; Peehl, D. M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res., 2001, 61 (7), 2852-2856.
230. Radermacher, J.; Diesel, B.; Seifert, M.; Tilgen, W.; Reichrath, J.; Fischer, U.; Meese, E. Expression analysis of CYP27B1 in tumor biopsies and cell cultures. Anticancer Res., 2006, 26 (4A), 2683-2686.
231. Schwartz, G. G.; Eads, D.; Rao, A.; Cramer, S. D.; Willingham, M. C.; Chen, T. C.; Jamieson, D. P.; Wang, L.; Burnstein, K. L.; Holick, M. F.; Koumenis, C. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis, 2004, 25 (6), 1015-1026.
232. Khadzkou, K.; Buchwald, P.; Westin, G.; Dralle, H.; Akerström, G.; Hellman, P. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J. Histochem. Cytochem., 2006, 54 (3), 355-361.
233. Evans, K. N.; Taylor, H.; Zehnder, D.; Kilby, M. D.; Bulmer, J. N.; Shah, F.; Adams, J. S.; Hewison, M. Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am. J. Pathol., 2004, 165 (3), 807-813.
234. Chen, G.; Kim, S. H.; King, A. N.; Zhao, L.; Simpson, R. U.; Christensen, P. J.; Wang, Z.; Thomas, D. G.; Giordano, T. J.; Lin, L.; Brenner, D. E.; Beer, D. G.; Ramnath, N. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin. Cancer Res., 2011, 17 (4), 817-826.
235. Blomberg Jensen, M.; Andersen, C. B.; Nielsen, J. E.; Bagi, P.; Jørgensen, A.; Juul, A.; Leffers, H. Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J. Steroid Biochem. Mol. Biol., 2010, 121 (1-2), 376-382.
236. Mitschele, T.; Diesel, B.; Friedrich, M.; Meineke, V.; Maas, R. M.; Gärtner, B. C.; Kamradt, J.; Meese, E.; Tilgen, W.; Reichrath, J. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest, 2004, 84 (6), 693-702.
237. Balla, B.; Kósa, J. P.; Tobiás, B.; Halászlaki, C.; Takács, I.; Horváth, H.; Speer, G.; Nagy, Z.; Horányi, J.; Járay, B.; Székely, E.; Lakatos, P. Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid, 2011, 21 (4), 459-460.